Literature DB >> 10711354

Clotrimazole inhibits the recombinant human cardiac L-type Ca2+ channel alpha 1C subunit.

I M Fearon1, S G Ball, C Peers.   

Abstract

1. Clotrimazole (CLT) is an antimycotic agent with a potential role in the treatment of cancer. Whole-cell patch clamp recordings and Fura-2 AM fluorescence measurements were used to investigate the inhibition by CLT of recombinant human cardiac L-type Ca2+ channel alpha 1C subunits, stably expressed in human embryonic kidney (HEK 293) cells. 2. CLT (100 nmol l-1 to 25 mumol l-1) reduced Ca2+ channel currents in a concentration-dependent manner. Inhibition was neither use- or voltage-dependent. The effects of CLT were rapid and maximal effects were attained within 3 min. Application of CLT also caused an acceleration of apparent Ca2+ channel current inactivation. 3. Basal current density and the degree of inhibition due to CLT were not significantly altered by pretreating cells with 3 mmol l-1 1-aminobenzotriazole for 1 h, or by dialysing cells for 10 min with 2 mmol l-1 alpha-napthoflavone via the patch pipette, suggesting that the inhibitory action of CLT was not due to inhibition of cytochrome P-450. 4. CLT (10 mumol l-1) did not influence [Ca2+]i, as determined by Fura-2 AM fluorescence measurements. 5. Dialysing cells for 10 min with the non-specific serine/threonine kinase inhibitor H-7 (10 mumol l-1) was without effect on basal current density or on the inhibitory response to 10 mumol l-1 CLT, indicating that CLT is not acting via an indirect effect on these kinases. 6. These data suggest that CLT exerts a direct blocking effect on the alpha 1C subunit at therapeutic concentrations. This effect may explain the abbreviation of the action potential duration by CLT observed in cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711354      PMCID: PMC1571876          DOI: 10.1038/sj.bjp.0703106

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Beta-subunit expression is required for cAMP-dependent increase of cloned cardiac and vascular calcium channel currents.

Authors:  U Klöckner; K Itagaki; I Bodi; A Schwartz
Journal:  Pflugers Arch       Date:  1992-03       Impact factor: 3.657

Review 2.  Structural basis of selective cytochrome P450 inhibition.

Authors:  J R Halpert
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

Review 3.  Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents.

Authors:  M Murray; G F Reidy
Journal:  Pharmacol Rev       Date:  1990-06       Impact factor: 25.468

4.  Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites.

Authors:  I Coupry; C C Armsby; S L Alper; C Brugnara; A Parini
Journal:  Eur J Pharmacol       Date:  1996-01-04       Impact factor: 4.432

5.  Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart.

Authors:  D Schultz; G Mikala; A Yatani; D B Engle; D E Iles; B Segers; R J Sinke; D O Weghuis; U Klöckner; M Wakamori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

7.  High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors.

Authors:  J Alvarez; M Montero; J Garcia-Sancho
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

8.  Agonist-induced Ca2+ influx in human neutrophils is secondary to the emptying of intracellular calcium stores.

Authors:  M Montero; J Alvarez; J Garcia-Sancho
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

9.  Calcium-mediated inactivation of the calcium conductance in caesium-loaded giant neurones of Aplysia californica.

Authors:  R Eckert; D L Tillotson
Journal:  J Physiol       Date:  1981-05       Impact factor: 5.182

10.  Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.

Authors:  C Brugnara; B Gee; C C Armsby; S Kurth; M Sakamoto; N Rifai; S L Alper; O S Platt
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

View more
  6 in total

1.  CACNA1S haploinsufficiency confers resistance to New World arenavirus infection.

Authors:  Nicolás Sarute; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

2.  Clotrimazole analogues: effective blockers of the slow afterhyperpolarization in cultured rat hippocampal pyramidal neurones.

Authors:  M M Shah; Z Miscony; M Javadzadeh-Tabatabaie; C R Ganellin; D G Haylett
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Sexually dimorphic response of TRPM2 inhibition following cardiac arrest-induced global cerebral ischemia in mice.

Authors:  S Nakayama; R Vest; R J Traystman; P S Herson
Journal:  J Mol Neurosci       Date:  2013-03-27       Impact factor: 3.444

4.  Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole.

Authors:  K Hill; S McNulty; A D Randall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-30       Impact factor: 3.000

5.  KCa3.1/IK1 Channel Regulation by cGMP-Dependent Protein Kinase (PKG) via Reactive Oxygen Species and CaMKII in Microglia: An Immune Modulating Feedback System?

Authors:  Roger Ferreira; Raymond Wong; Lyanne C Schlichter
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

Review 6.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 1: Modulation of TRPM4.

Authors:  Zsigmond Máté Kovács; Csaba Dienes; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.